Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 7Active not recruiting 6Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 60Genitourinary 13Gynecologic 10Thoracic 6Other solid neoplasm 5Head & Neck 5Breast 5Endocrine 3Tumor-Agnostic 2Sarcoma 2Other hematologic neoplasm 1NET 1CNS 1

Conditions

Thyroid Carcinoma, Anaplastic 1Neuroendocrine Tumors 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × lenvatinib × Endocrine × Clear all
NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Saint Petersburg State University, Russia

Phase 2 Recruiting
20 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡